Predictors of High SARS-CoV-2 Immunoglobulin G Titers in COVID-19 Convalescent Whole-blood Donors: a Cross-sectional Study in China

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Jun 30

PMID 37388736

Authors

Jingyun Tang

Humin Liu

Qing Wang

Xiaobo Gu

Jia Wang

Wenjun Li

Yinglan Luo

Yan Li

Lan Deng

Yue Luo

Xinman Du

Donglin Tan

Xuemei Fu

Xue Chen

Affiliations

Soon will be listed here.

Abstract

Background: Demographic information has been shown to help predict high antibody titers of COVID-19 convalescent plasma (CCP) in CCP donors. However, there is no research on the Chinese population and little evidence on whole-blood donors. Therefore, we aimed to investigate these associations among Chinese blood donors after SARS-CoV-2 infection.

Methods: In this cross-sectional study, 5,064 qualified blood donors with confirmed or suspected SARS-CoV-2 infection completed a self-reported questionnaire and underwent tests of SARS-CoV-2 Immunoglobulin G (IgG) antibody and ABO blood type. Logistic regression models were used to calculate odds ratios (ORs) for high SARS-CoV-2 IgG titers according to each factor.

Results: Totally, 1,799 participants (with SARS-CoV-2 IgG titers≥1:160) had high-titer CCPs. Multivariable analysis showed that a 10-year increment in age and earlier donation were associated with higher odds of high-titer CCP, while medical personnel was associated with lower odds. The ORs (95% CIs) of high-titer CCP were 1.17 (1.10-1.23, p< 0.001) and 1.41 (1.25-1.58, p< 0.001) for each 10-year increment in age and earlier donation, respectively. The OR of high-titer CCP was 0.75 (0.60-0.95, p = 0.02) for medical personnel. Female early donors were associated with increased odds of high-titer CCP, but this association was insignificant for later donors. Donating after 8 weeks from the onset was associated with decreased odds of having high-titer CCP compared to donating within 8 weeks from the onset, and the HR was 0.38 (95% CI: 0.22-0.64, p <0.001). There was no significant association between ABO blood type or race and the odds of high-titer CCP.

Discussion: Older age, earlier donation, female early donors, and non-medical-related occupations are promising predictors of high-titer CCP in Chinese blood donors. Our findings highlight the importance of CCP screening at the early stage of the pandemic.

Citing Articles

Factors associated with the SARS-CoV-2 immunoglobulin-G titer levels in convalescent whole-blood donors: a Chinese cross-sectional study.

Tan D, Du X, Tang J, Liu H, Li M, Kang J Sci Rep. 2024; 14(1):6072.

PMID: 38480826 PMC: 10937670. DOI: 10.1038/s41598-024-56462-y.

References

Masia M, Fernandez-Gonzalez M, Telenti G, Agullo V, Garcia J, Padilla S . Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study. J Autoimmun. 2021; 123:102703. PMC: 8289631. DOI: 10.1016/j.jaut.2021.102703. View

Chvatal-Medina M, Mendez-Cortina Y, Patino P, Velilla P, Rugeles M . Antibody Responses in COVID-19: A Review. Front Immunol. 2021; 12:633184. PMC: 8081880. DOI: 10.3389/fimmu.2021.633184. View

Ho J, Sepand M, Bigdelou B, Shekarian T, Esfandyarpour R, Chauhan P . The immune response to COVID-19: Does sex matter?. Immunology. 2022; 166(4):429-443. PMC: 9111683. DOI: 10.1111/imm.13487. View

Focosi D, McConnell S, Casadevall A . The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies. Drug Resist Updat. 2022; 65:100882. PMC: 9528072. DOI: 10.1016/j.drup.2022.100882. View

Gallian P, Le Cam S, Brisbarre N, Pastorino B, Amroun A, Malard L . COVID-19 convalescent plasma: Evolving strategies for serological screening in France. Vox Sang. 2021; 117(4):606-610. DOI: 10.1111/vox.13228. View

Notarte K, Guerrero-Arguero I, Velasco J, Ver A, de Oliveira M, Catahay J . Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review. J Med Virol. 2022; 94(7):2939-2961. PMC: 9088566. DOI: 10.1002/jmv.27688. View

Sullivan D, Franchini M, Joyner M, Casadevall A, Focosi D . Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources. Nat Commun. 2022; 13(1):6478. PMC: 9617541. DOI: 10.1038/s41467-022-33864-y. View

Schmidt A, Vogel P, Chastain C, Barnes T, Roth N, Simon T . Analysis of 52 240 source plasma donors of convalescent COVID-19 plasma: Sex, ethnicity, and age association with initial antibody levels and rate of dissipation. J Clin Apher. 2022; 37(5):449-459. PMC: 9350246. DOI: 10.1002/jca.21998. View

Estcourt L, Cohn C, Pagano M, Iannizzi C, Kreuzberger N, Skoetz N . Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma. Ann Intern Med. 2022; 175(9):1310-1321. PMC: 9450870. DOI: 10.7326/M22-1079. View

10.

Suzuki T, Asai Y, Ide S, Fukuda S, Tanaka A, Shimanishi Y . Factors associated with high antibody titer following coronavirus disease among 581 convalescent plasma donors: A single-center cross-sectional study in Japan. J Infect Chemother. 2021; 28(2):206-210. PMC: 8526427. DOI: 10.1016/j.jiac.2021.10.012. View

11.

Mehew J, Johnson R, Roberts D, Griffiths A, Harvala H . Convalescent plasma for COVID-19: Donor demographic factors associated high neutralising antibody titres. Transfus Med. 2022; 32(4):327-337. PMC: 9115414. DOI: 10.1111/tme.12868. View

12.

Korper S, Jahrsdorfer B, Corman V, Pilch J, Wuchter P, Blasczyk R . Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies. Transfus Med Hemother. 2021; 48(3):137-147. PMC: 8216018. DOI: 10.1159/000515610. View

13.

Schlickeiser S, Schwarz T, Steiner S, Wittke K, Besher N, Meyer O . Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses. Front Immunol. 2021; 11:628971. PMC: 7878374. DOI: 10.3389/fimmu.2020.628971. View

14.

. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet. 2022; 399(10334):1513-1536. PMC: 8912932. DOI: 10.1016/S0140-6736(21)02796-3. View

15.

Girardin R, Dupuis A, Payne A, Sullivan T, Strauss D, Parker M . Temporal Analysis of Serial Donations Reveals Decrease in Neutralizing Capacity and Justifies Revised Qualifying Criteria for Coronavirus Disease 2019 Convalescent Plasma. J Infect Dis. 2021; 223(5):743-751. PMC: 7928872. DOI: 10.1093/infdis/jiaa803. View

16.

Hayes C, Rubenstein W, Gibb D, Klapper E, Tanaka J, Pepkowitz S . Blood group O convalescent plasma donations have significantly lower levels of SARS-CoV-2 IgG antibodies compared to blood group A donations. Transfusion. 2021; 61(8):2245-2249. PMC: 8242504. DOI: 10.1111/trf.16524. View

17.

Dutra V, Bonet-Bub C, Yokoyama A, Achkar R, Machado R, Assuncao M . Anti-A and SARS-CoV-2: an intriguing association. Vox Sang. 2021; 116(5):557-563. PMC: 8013368. DOI: 10.1111/vox.13044. View

18.

Tobian A, Cohn C, Shaz B . COVID-19 convalescent plasma. Blood. 2021; 140(3):196-207. PMC: 8548835. DOI: 10.1182/blood.2021012248. View

19.

Focosi D, Franchini M, Pirofski L, Burnouf T, Paneth N, Joyner M . COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. Clin Microbiol Rev. 2022; 35(3):e0020021. PMC: 9491201. DOI: 10.1128/cmr.00200-21. View

20.

Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M . Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect Dis. 2022; 22(11):e311-e326. PMC: 9255948. DOI: 10.1016/S1473-3099(22)00311-5. View